Moffitt Cancer Center Logo
 

Geoffrey T. Gibney, MD

Where You Are:

Geoffrey T. Gibney, MD

Medical Oncology

For Consultation Requests or Referrals: (813) 745-8482

 
 

BOARD CERTIFICATION:
          •  Internal Medicine - Medical Oncology

FELLOWSHIP:
          •  Yale University/Yale Cancer Center - Hematology/Medical Oncology

RESIDENCY:
          •  Boston University Medical Center - Internal Medicine

MEDICAL SCHOOL:
          •  University of Connecticut School of Medicine - MD

  • Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amavaradi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res. 2014 May;27(3):465-478. Pubmedid: 24490764.

  • Sloot S, Fedorenko IV, Smalley KS, Gibney GT. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?. Expert Opin Pharmaco. 2014 Apr;15(5):589-592. Pubmedid: 24456413.

  • Forsyth PA, Krishna N, Lawn S, Valadez JG, Qu X, Fenstermacher DA, Fournier M, Potthast L, Chinnaiyan P, Gibney GT, Zeinieh M, Barker PA, Carter BD, Cooper MK, Kenchappa RS. p75 Neurotrophin Receptor Cleavage by ?- and ?-Secretases Is Required for Neurotrophin-mediated Proliferation of Brain Tumor-initiating Cells. J Biol Chem. 2014 Mar;289(12):8067-8085. Pubmedid: 24519935.

  • Kudchadkar R, Gibney G, Sondak VK. Integrating molecular biomarkers into current clinical management in melanoma. Methods Mol Biol. 2014;1102:27-42. Pubmedid: 24258972.

  • Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, Kroeger J, Eysmans C, Sarnaik AA, Chen YA. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013 Dec;31(34):4311-4318. Pubmedid: 24145345. Pmcid: PMC3837092.

  • Weber JL, Smalley KS, Sondak VK, Gibney GT. Conjunctival Melanomas Harbor BRAF and NRAS Mutations--Letter. Clin Cancer Res. 2013 Nov;19(22):6329-6330. Pubmedid: 24166902.

  • Kenchappa RS, Tran N, Rao NG, Smalley KS, Gibney GT, Sondak VK, Forsyth PA. Novel treatments for melanoma brain metastases. Cancer Control. 2013 Oct;20(4):298-306. Pubmedid: 24077406.

  • Zager JS, Sarnaik AA, Gibney GT, Kudchadkar RR. Recent advances in the treatment of melanoma. Cancer Control. 2013 Oct;20(4):244-245. Pubmedid: 24077400.

  • Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013 Jul;10(7):390-399. Pubmedid: 23712190. Pmcid: PMC3983565.

  • Gibney GT, Sondak VK. Has targeted therapy for melanoma made chemotherapy obsolete?. Lancet Oncol. 2013 Jul;14(8):676-677. Pubmedid: 23816289.

  • Fedorenko IV, Gibney GT, Smalley KS. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene. 2013 Jun;32(25):3009-3018. Pubmedid: 23069660. Pmcid: PMC3978385.

  • Lo RS, Ribas A, Long GV, Ballotti R, Berger M, Willy H, Gibney GT, Bosenberg M, Bernstein E, Villanueva J, Smalley KS. Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California. Pigment Cell Melanoma Res. 2013 Apr;26(4):E1-E7. Pubmedid: 23551976.

  • Gibney GT, Zager JS. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opin Drug Metab Toxicol. 2013 Apr;9(7):893-899. Pubmedid: 23621583.

  • Gibney GT, Weber JS. Expanding targeted therapy to NRAS-mutated melanoma. Lancet Oncol. 2013 Mar;14(3):186-188. Pubmedid: 23414591.

  • Gibney GT, Smalley KS. An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance. Cancer Discov. 2013 Mar;3(3):260-263. Pubmedid: 23475878. Pmcid: PMC3595124.

  • Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013 Feb;24(2):343-349. Pubmedid: 23022995. Pmcid: PMC3551486.

  • Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mul? JJ, Sarnaik AA. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012 Oct;35(8):615-620. Pubmedid: 22996367.

  • Gibney GT, Forsyth PA, Sondak VK. Melanoma in the brain: biology and therapeutic options. Melanoma Res. 2012 Jun;22(3):177-183. Pubmedid: 22495668.

  • Gibney GT, Sondak VK. Extending the reach of BRAF-targeted cancer therapy. Lancet. 2012 May;379(9829):1858-1859. Pubmedid: 22608322.

  • Verhovsek M, So CC, O'Shea T, Gibney GT, Ma ES, Steinberg MH, Chui DH. Is HbA(2) level a reliable diagnostic measurement for ?-thalassemia trait in people with iron deficiency?. Am J Hematol. 2012 Jan;87(1):114-116. Pubmedid: 22038702.

  • Gibney GT, Panhuysen CI, So JC, Ma ES, Ha SY, Li CK, Lee AC, Li CK, Yuen HL, Lau YL, Johnson DM, Farrell JJ, Bisbee AB, Farrer LA, Steinberg MH, Chan LC, Chui DH. Variation and heritability of Hb F and F-cells among beta-thalassemia heterozygotes in Hong Kong. Am J Hematol. 2008 Jun;83(6):458-464. Pubmedid: 18266208.

  • Hong SS, Gibney GT, Esquilin M, Yu J, Xia Y. Effect of protein kinases on lactate dehydrogenase activity in cortical neurons during hypoxia. Brain Res. 2004 May;1009(1-2):195-202. Pubmedid: 15120597.

  • Zhang J, Gibney GT, Zhao P, Xia Y. Neuroprotective role of delta-opioid receptors in cortical neurons. Am J Physiol Cell Physiol. 2002 Jun;282(6):C1225-C1234. Pubmedid: 11997236.

  • Gibney GT, Zhang JH, Douglas RM, Haddad GG, Xia Y. Na(+)/Ca(2+) exchanger expression in the developing rat cortex. Neuroscience. 2002;112(1):65-73. Pubmedid: 12044472.

  • Zhang JH, Gibney GT, Xia Y. Effect of prolonged hypoxia on Na+ channel mRNA subtypes in the developing rat cortex. Brain Res Mol Brain Res. 2001 Jul;91(1-2):154-158. Pubmedid: 11457503.

Dr. Geoffrey Gibney is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Departments of Oncologic Sciences and Internal Medicine at the University of South Florida.

Dr. Gibney is actively involved translational research in targeted therapies for melanoma and other skin cancers to develop personalized treatment strategies. He is investigating the role of receptor tyrosine kinases and intracellular proteins as biomarkers and therapeutic targets in cutaneous malignancies. This includes specific research in c-Met, Axl, PDGF-ß and the JAK2/STAT3 pathways in melanoma. He is also interested in integrating targeted therapeutics with immunotherapies.

In addition to translational research, he is the principle investigator of multiple clinical trials for melanoma therapies at Moffitt Cancer Center. He has a specific interest in treating patients with melanoma brain metastases and is a co-leader of the Neuro Melanoma program at Moffitt. He also treats patients with advanced non-melanoma skin cancers, such as basal cell carcinoma, squamous cell carcinoma, and merkel cell carcinoma.

After graduating from the University of Connecticut School of Medicine, Dr. Gibney completed a residency in internal medicine at the Boston University Medical Center and a clinical fellowship in medical oncology at the Yale Cancer Center-Yale University School of Medicine.  He joined Moffitt in 2011.